Navigation Links
eResearchTechnology Reports Fourth Quarter and Full Year 2007 Results
Date:2/26/2008

p> Preferred stock-$10.00 par value, 500,000

shares authorized, none issued and outstanding - -

Common stock-$.01 par value, 175,000,000 shares

authorized, 58,356,546 and 58,870,291 shares

issued, respectively 584 589

Additional paid-in capital 83,493 87,957

Accumulated other comprehensive income 1,510 1,679

Retained earnings 70,225 85,477

Treasury stock, 8,247,119 shares at cost (62,190) (62,190)

Total stockholders' equity 93,622 113,512

Total liabilities and stockholders'

equity $115,064 $147,696

eResearchTechnology, Inc. and Subsidiaries

Consolidated Statements of Cash Flows

(in thousands)

Year Ended December 31,

2006 2007

(unaudited)

Operating activities:

Net income $8,310 $15,252

Adjustments to reconcile net income to net

cash provided by operating activities:

Depreciation and amortization 11,253 15,129

Cost of sales of equipment 3,722 1,143

Provision for uncollectible accounts 111 30

Share-based compensation 2,975 2,004

Investment impairment charge 226 -

Changes in operating assets and liabilities

exclusive of CCSS acquisition:

Accounts receivable (2,56
'/>"/>

SOURCE eResearchTechnology, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related biology technology :

1. eResearchTechnology to Present at the Thomas Weisel Healthcare Conference 2007 on September 5th
2. eResearchTechnology to Present at the UBS Global Healthcare Services Conference 2008 on February 11th
3. eResearchTechnology, Inc. to Announce 2007 Fourth Quarter Results on February 26, 2008
4. EpiCept Reports Expansion of Clinical Development For Licensed Cancer Compound
5. QMed, Inc. Reports July Medicare SNP Enrollments
6. Phlo Affiliate Reports Expanded Coverage to Oregon Border
7. Healthcare Technologies Reports Loss for 2007 Second Quarter & Six Months Results
8. Dragon Pharmaceutical Reports Growth in Sales and Profits during Second Quarter of 2007
9. Carrington Reports Second Quarter 2007 Results
10. Avitar Reports Third Quarter Financial Results for Fiscal 2007
11. Response Genetics Reports Second Quarter 2007 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/22/2014)... 22, 2014   Synthetic Biologics, Inc. ... pathogen-specific therapies for serious infections and diseases, ... today announced positive topline safety and tolerability ... of SYN-004, the Company,s investigational oral beta-lactamase ... difficile (C. difficile) infection, antibiotic-associated diarrhea ...
(Date:12/22/2014)... Dec. 22, 2014 GenomeDx Biosciences today announced ... Cancer Classifier, a genomic test for prostate cancer, was ... men managed by radical prostatectomy without adjuvant therapy. Although ... relatively uncommon, using tumor genomics to identify these men ... is an important advance. The study has been ...
(Date:12/22/2014)... 22, 2014 ITRA Global, one of ... of commercial real estate, has further expanded its global ... Perth and Brisbane, Western Australia, reports Mylinda Vick, CCIM, ... ITRA Global / ACORPP (Australian Corporate Property and ... company providing property services to a wide range of ...
(Date:12/19/2014)... Charm Sciences is pleased to announce that ... Aflatoxin M1 in raw commingled milk is the first ... The peer reviewed report of the validation by Technology ... and Fisheries Research (ILVO-T&V) has been published by the ... most toxic aflatoxin and a known carcinogen, can be ...
Breaking Biology Technology:Synthetic Biologics Announces Positive Topline Results from Phase 1a Trial of SYN-004 for the Prevention of C. difficile Infection 2Synthetic Biologics Announces Positive Topline Results from Phase 1a Trial of SYN-004 for the Prevention of C. difficile Infection 3Synthetic Biologics Announces Positive Topline Results from Phase 1a Trial of SYN-004 for the Prevention of C. difficile Infection 4Synthetic Biologics Announces Positive Topline Results from Phase 1a Trial of SYN-004 for the Prevention of C. difficile Infection 5Study Published in European Urology Shows that the Decipher Prostate Cancer Classifier is Predictive of Rapid Metastasis in High-Risk Men who have had Prostate Surgery 2Study Published in European Urology Shows that the Decipher Prostate Cancer Classifier is Predictive of Rapid Metastasis in High-Risk Men who have had Prostate Surgery 3ITRA Global Continues International Expansion in Perth and Brisbane, Australia 2Charm Sciences Achieves Independent Validation of First 15 Minute Quantitative Screening Method for Aflatoxin M1 2
... NATICK, Mass. and SAN FRANCISCO, Nov. 8, 2011 ... ) reports positive long-term data from the PERSEUS ... effectiveness outcomes for the ION™ (TAXUS Element) Paclitaxel-Eluting ...  Results were presented today by PERSEUS clinical program ...
... SQUARE, Pa., Nov. 8, 2011 Kibow Biotech, Inc. ... of Renal Week, it is changing the brand name ... Kibow® Biotics, this patented and clinically tested probiotic formulation ... there is growing recognition of the scientific and health ...
... Valkee ( http://valkee.com ), the inventor ... from the University of Oulu present two clinical trials ... Anxiety Disorders in Budapest on November 9 th -11 ... the peer-reviewed conference supplement of the International Journal of ...
Cached Biology Technology:Boston Scientific Platinum Chromium ION™ Stent Demonstrates Positive Outcomes in PERSEUS Clinical Program 2Boston Scientific Platinum Chromium ION™ Stent Demonstrates Positive Outcomes in PERSEUS Clinical Program 3Boston Scientific Platinum Chromium ION™ Stent Demonstrates Positive Outcomes in PERSEUS Clinical Program 4Boston Scientific Platinum Chromium ION™ Stent Demonstrates Positive Outcomes in PERSEUS Clinical Program 5Kibow Changes Name of Flagship Kidney Function Support Product to 'RENADYL™' 2Bright Light into the Ear Canal Treats Seasonal Depression Effectively in Two Clinical Trials Presented by Valkee and University of Oulu 2Bright Light into the Ear Canal Treats Seasonal Depression Effectively in Two Clinical Trials Presented by Valkee and University of Oulu 3
(Date:12/17/2014)... 2014 Research and Markets ( ... "Global Chemical Sensor Market 2015-2019" report ... http://photos.prnewswire.com/prnh/20130307/600769 One major trend upcoming ... medical sensors in biomedical applications. Chemical sensors help ... correct diagnosis during surgical procedures. The Global Chemical ...
(Date:12/11/2014)... , Dec. 09, 2014 Research and ... ( http://www.researchandmarkets.com/research/9ql3kr/biometrics_market ) has ... in India 2015-2019" report to their offering. ... this market is the adoption of multimodal biometric ... characteristic of an individual for verification and identification ...
(Date:12/10/2014)...  Valencell, a leader in performance biometric data sensor ... from its licensees for highly accurate, clinically validated biometric ... coming from fitness and health sectors, but first responders/military ... is only as useful as the biometric data it ... in long-term mass consumer adoption of wearable products," said ...
Breaking Biology News(10 mins):Global Chemical Sensor Market 2015-2019: Key Vendors are Abbott Laboratories, Bayer, Hoffmann La-Roche, Johnson & Johnson, NGK Spark Plugs and Robert Bosch 2Biometrics Market in India 2015-2019: Key Vendors are 3M Cogent, NEC, Safran and Suprema 2Wearable Technology Products Demand Highly Accurate Biometric Technology 2
... Cambridge, Mass., and Worcester, Mass., March 1, 2012 ... RNAi therapeutics company, and the University of Massachusetts ... Patent Office (EPO) has upheld the Tuschl I ... held in Munich, Germany. The requested claims of ...
... Italian and Swiss researchers confirm that induced hyperammonaemia significantly ... available in the March issue of Hepatology , ... American Association for the Study of Liver Diseases, show ... of cirrhotic patients to produce restorative sleep. ...
... with implants. Often following the procedure, they are unable to ... has become fixated in the bone. Now, for the first ... allows titanium screws to adhere to the bone better and ... results are good. The study, led by Per Aspenberg, ...
Cached Biology News:Alnylam and UMass Medical School announce Tuschl I patent upheld in European opposition proceedings 2Alnylam and UMass Medical School announce Tuschl I patent upheld in European opposition proceedings 3Cirrhotic patients experience increased daytime sleepiness from higher ammonia levels 2New method for stronger dental implants 2
Mouse monoclonal antibody raised against a partial recombinant TTC3. NCBI Entrez Gene ID = TTC3...
... Mouse monoclonal antibody raised against ... Immunogen: TOPORS ... a.a) partial recombinant protein with ... Accession Number: NM_005802 ...
Mouse monoclonal antibody raised against a partial recombinant PASK. NCBI Entrez Gene ID = PASK...
Agarose II (Low Melt)...
Biology Products: